Analysts expect Nektar Therapeutics to report revenue of 10.51 M for Q3 26, against a range of 9.77 M to 11.26 M. The most recent reported quarter, Q2 26, came in at 10.13 M, a 0.9% beat against the 10.04 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 24.12 M | 29.18 M | 10.46 M | 11.18 M | 11.79 M | 21.81 M | 10.86 M | 10.13 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 19.19 M | 35.44 M | 15.61 M | 10.12 M | 10.09 M | 11.29 M | 10.40 M | 10.39 M | 11.26 M | 10.59 M | 10.46 M | 11.15 M | 10.58 M | 13.35 M | 9.40 M | 10.61 M | ||||||||||
| Low Estimate | 16.69 M | 31.26 M | 13.57 M | 8.32 M | 8.99 M | 10.52 M | 9.71 M | 9.69 M | 9.77 M | 8.96 M | 9.11 M | 9.86 M | 9.72 M | 12.08 M | 8.11 M | 9.22 M | ||||||||||
| Consensus Estimate | 17.94 M | 33.35 M | 14.59 M | 9.22 M | 9.54 M | 10.90 M | 10.05 M | 10.04 M | 10.51 M | 9.78 M | 9.79 M | 10.50 M | 10.15 M | 12.72 M | 8.75 M | 9.91 M |
Analysts expect Nektar Therapeutics to report earnings per share of -2.02 for Q3 26, against a range of -2.17 to -1.87. The most recent reported quarter, Q2 26, came in at -1.23, a 41.4% beat against the -2.10 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.70 | 0.45 | -3.60 | -2.95 | -1.87 | -1.78 | -1.82 | -1.23 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -2.96 | -1.95 | -2.43 | -2.95 | -2.46 | -2.37 | -1.56 | -1.99 | -1.87 | -2.79 | -2.72 | -2.61 | -2.42 | -2.57 | -2.85 | -2.27 | ||||||||||
| Low Estimate | -3.32 | -2.33 | -2.79 | -3.33 | -2.70 | -2.87 | -1.76 | -2.21 | -2.17 | -3.07 | -3.22 | -3.07 | -2.68 | -2.95 | -3.31 | -2.71 | ||||||||||
| Consensus Estimate | -3.14 | -2.14 | -2.61 | -3.14 | -2.58 | -2.62 | -1.66 | -2.10 | -2.02 | -2.93 | -2.97 | -2.84 | -2.55 | -2.76 | -3.08 | -2.49 |
Pull Wall Street consensus for Nektar Therapeutics (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NKTR&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NKTR", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NKTR&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();